The aim of this study was to assess the efficacy of daily intravaginal administration of 0.50% DHEA for a 12-week period, on moderate to severe dyspareunia in post-menopausal women with vulvovaginal atrophy. After 12 weeks of treatment, 11 serum sex steroids levels were measured, and the researchers found that they all remained within the normal post-menopausal values. Specifically, serum estradiol was found to be around 22% below average normal post-menopausal values. This finding confirms that there is intracellular transformation of DHEA in the vagina resulting in local efficacy.
